Imatinib mesylate induced erythroderma: A rare case report

---

Case Report

Author Details : Snehal Balvant Lunge, Rohan Bhise

Volume : 3, Issue : 2, Year : 2017

Article Page : 88-90

Suggest article by email

Get Permission

---

Abstract

Imatinib, a specific tyrosine kinase inhibitor is a newer anticancer agent, which has shown excellent efficacy in managing chronic myeloid leukemia. It is generally well tolerated with few side effects. Most commonly reported adverse events are maculopapular eruptions and periorbital edema. Severe adverse reactions are seen in 5% of patients. Exfoliative dermatitis has been very rarely reported with this drug. We report a case of a 55-year-old female who initially presented with a maculopapular rash and developed erythroderma on continuation of the drug.

Keywords: Imatinib mesylate, Adverse cutaneous drug reaction, Erythroderma

How to cite : Lunge S B, Bhise R, Imatinib mesylate induced erythroderma: A rare case report. IP Indian J Clin Exp Dermatol 2017;3(2):88-90

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.